Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $37.5452W HIGH $59.68
Volume
1.88 M
Value Traded
35.88 M
Short % Float
7.42%
Days to Cover
4.9
+2.8%Week
-2.79%1 Month
-6.25%3 Month
-12.56%6 Month
+53.19%5 Year
+641.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.44 B
EPS (TTM)
-1.89
P/E Ratio
-
Ent. Value
2.08 B
Total Shares
58.22 M
Float Shares
54.53 M
Insiders
6.34%
Institutions
102.25%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SUPN Catalyst Timeline
Dated clinical, regulatory and corporate events for Supernus Pharmaceuticals, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Supernus Pharmaceuticals, Inc.
671Total events
10Upcoming
168Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Exclusivity GrantedOnapgo (SPN-830)ApprovedIP / Competition
FDA recognized seven years of orphan-drug exclusivity for ONAPGO
motor fluctuations in adults with advanced Parkinson's diseasesource ↗
●sNDA SubmissionOnapgo (SPN-830)ApprovedRegulatory Filing
sNDA submitted to FDA for a second supplier for ONAPGO
motor fluctuations in adults with advanced Parkinson's diseasesource ↗
●Quarterly UpdateCorporate
Q2 2026 financial results to be reported in separate press releases
▲Quarterly UpdateCorporate
Approximately 3 million prescriptions filled since launch, over 1 million in 2025
●NDA SubmissionOnapgo (SPN-830)ApprovedRegulatory Filing
Regulatory submission to FDA for second supplier for ONAPGO
◆Milestone PaymentZURZUVAECorporate
CVR milestone: first commercial sale in Japan for MDD after regulatory approval by June 30, 2026
major depressive disordersource ↗
◆Other Regulator MilestoneZURZUVAEEx-US Regulatory
First commercial sale after regulatory approval in Japan for ZURZUVAE in MDD
Major Depressive Disordersource ↗
◆Product LaunchZURZUVAEPost-Market
First commercial sale of ZURZUVAE in Japan for MDD
Major Depressive Disordersource ↗
◆Oral PresentationPresentation
Supernus management to participate in Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Supernus management to participate in Jefferies Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Supernus Pharmaceuticals to participate in fireside chat at Bank of America 2026 Health Care Conference
◆Oral PresentationPresentation
Barclays 28th Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Supernus Pharmaceuticals presentation at Bank of America Securities 2025 CNS Therapeutics Virtual Conference
◆Oral PresentationPresentation
Supernus Pharmaceuticals to participate in Piper Sandler 37th Annual Healthcare Conference fireside chat
◆Oral PresentationPresentation
Supernus participates in fireside chat at 2025 Jefferies Global Healthcare Conference in London
◆Oral PresentationPresentation
TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit fireside chat
◆Oral PresentationPresentation
Supernus participates in 2025 Jefferies Global Healthcare Conference fireside chat
◆Para Iv CertificationQelbreeApprovedIP / Competition
Paragraph IV ANDA filings for Qelbree received
ADHDsource ↗
◆Oral PresentationQelbreeApprovedPresentation
Topline results from full Phase IV trial to be presented at APA Annual Meeting
ADHD with mood symptomssource ↗
▲Product LaunchOnapgo (SPN-830)ApprovedPost-Market
ONAPGO launched in the U.S.
motor fluctuations in adults with advanced Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Supernus participates in TD Cowen 45th Annual Health Care Conference
▼Primary Endpoint MissedSPN-820Clinical Data
Phase 2b study of SPN-820 in TRD did not meet primary endpoint
treatment-resistant depressionsource ↗
▲FDA ApprovalOnapgo (SPN-830)ApprovedFDA Decision
FDA approval of ONAPGO for motor fluctuations in advanced Parkinson's disease
Parkinson's diseasesource ↗
◆PDUFA DateSPN-830FiledRegulatory Filing
PDUFA date for SPN-830 set to February 1, 2025
Parkinson's disease motor fluctuationssource ↗
▲FDA ApprovalOnapgo (SPN-830)ApprovedFDA Decision
FDA approval of ONAPGO (apomorphine hydrochloride) for motor fluctuations in advanced PD
Parkinson's diseasesource ↗
▲Label ExpansionQelbreeApprovedFDA Decision
FDA approval of Qelbree label update including pharmacodynamic and lactation data
ADHDsource ↗
▲Patent GrantedQelbreeApprovedIP / Competition
Patent term extension for US Patent No. 9,662,338 covering Qelbree to 2035
ADHDsource ↗
▲Interim AnalysisQelbreeApprovedTrial
Interim results from open-label Phase IV trial in adults with ADHD and mood symptoms presented at conference
ADHD with mood symptomssource ↗
Past FDA Catalysts and PDUFA Decisions
How SUPN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-06-30 | SPN-820 | Phase 2b topline data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
7
Drugs Scored
rNPV / MCap
Top Drug
Top 14%
Small Cap(rank 93 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Qelbree | |||
| GOCOVRI | |||
| ONAPGO | |||
| Trokendi XR | |||
| Oxtellar XR | |||
| APOKYN |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPN-817 Small moleculeNCT07141329 | Focal Onset Seizures | Phase 2 | ENROLLING BY_INVITATION | 316 | Dec 31, 2027 | ||||||
| SPN-817 Small moleculeNCT05518578 | Epilepsy | Phase 2 | RECRUITING | 60 | Dec 31, 2027 | ||||||
| BIS-001ER Small moleculeNCT03474770 | Focal Impaired Awareness Seizures | Phase 1 | ACTIVE NOT_RECRUITING | 16 | Dec 30, 2026 | ||||||
| SPN-821 Small moleculeNCT07226661 | Major Depressive Disorder (MDD) | Phase 2 | RECRUITING | 230 | Jan 31, 2027 | ||||||
| SPN-812 Small moleculeMarketedNCT02736656 | Attention-Deficit/Hyperactivity Disorder | Phase 3 | ACTIVE NOT_RECRUITING | 2,155 | Sep 1, 2026 | ||||||
| Onapgo (SPN-830) Small moleculeMarketedNCT02339064 | Idiopathic Parkinson's Disease | Phase 3 | ACTIVE NOT_RECRUITING | 99 | Dec 1, 2025 | ||||||
| SAGE-718 Small moleculeCompletedNCT03787758 | Huntington Disease | Phase 2 | COMPLETED | 264 | Oct 7, 2019 | ||||||
| SAGE-718 Small moleculeCompletedNCT05318937 | Parkinson Disease | Phase 2 | COMPLETED | 104 | Feb 23, 2024 | ||||||
| SAGE-718 Small moleculeCompletedNCT05619692 | Mild Cognitive Impairment | Phase 2 | COMPLETED | 174 | Jul 9, 2024 | ||||||
| NV-5138 Small moleculeCompletedNCT05066672 | Treatment Resistant Depression | Phase 2 | COMPLETED | 250 | Jan 21, 2025 | ||||||
| NV-5138 Small moleculeCompletedNCT06235905 | Major Depressive Disorder | Phase 2 | COMPLETED | 40 | Aug 18, 2024 | ||||||
| Brexanolone Small moleculeCompletedNCT05645432 | Tinnitus | Phase 2 | COMPLETED | 10 | Nov 21, 2023 | ||||||
| SAGE-904 Small moleculeCompletedNCT05049343 | Undisclosed | Phase 1 | COMPLETED | 22 | Dec 3, 2021 | ||||||
| SPN-812 Small moleculeMarketedNCT03247543 | ADHD | Phase 3 | COMPLETED | 1,397 | Oct 17, 2018 | ||||||
| Oxcarbazepine Small moleculeMarketedNCT00908349 | Partial Epilepsy | Phase 3 | COMPLETED | 214 | Nov 1, 2011 | ||||||
| SPN-804 Small moleculeMarketedNCT00772603 | Epilepsies, Partial | Phase 3 | COMPLETED | 366 | Nov 1, 2010 | ||||||
| ADS-5102 Small moleculeMarketedNCT01397422 | Dyskinesia | Phase 3 | COMPLETED | 509 | Oct 1, 2013 | ||||||
| Botulinum Toxin Type B Monoclonal antibodyMarketedNCT00515437 | Drooling | Phase 2 | COMPLETED | 54 | Sep 1, 2008 | ||||||
| IR Viloxazine Small moleculeMarketedNCT01107496 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1 | COMPLETED | 52 | Dec 1, 2010 | ||||||
| Topiramate IR Small moleculeMarketedNCT01114854 | Epilepsy | Phase 1 | COMPLETED | 69 | Jan 1, 2011 | ||||||
| TPM Small moleculeMarketedNCT01284530 | Epilepsy | Phase 1 | COMPLETED | 30 | Jun 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every SUPN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| SPN-820 | treatment-resistant depression | Phase 2b | 2025-02-18 | SPN-820 LS mean Standard Error -12.3 0.96 vs. placebo -11.9 0.96 p not significantRead More | Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptomsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rubin JonathanOfficer (SVP, Chief Medical Officer) | Option | 750 14,342 held | $0.00 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SUPN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 2.5 % (31.6 %) | 48.20 M | 1.04 M | 8.59% ( 82.02 K) |
SUPN Institutional Ownership Trends
SUPN Short Interest
Shares sold short, counted twice a month.
7.42%
Short % of Float
of tradable shares sold short
4.0M
Shares Sold Short
-18.9% vs prior count
4.9 Moderate
Days to Cover
trading days of normal volume to buy every short share back
819.9K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SUPN ranks across every disease it competes in
Competitive Position is a premium feature
See how SUPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSUPN News
SUPN▲ +1.9%today
Supernus Announces Third Quarter 2026 Financial Results
Supernus Pharmaceuticals reported record revenues of $226.8 million for Q3 2026, an 18% increase year-over-year. The company's four growth products generated $192.2 million, a 29% rise. Supernus also received orphan-drug approval for ONAPGO and is set to merge with Indivior on November 2, 2026.
Read more →SUPN▲ +1.9%today
Chloe Kim Is Changing the Conversation Around ADHD in Women with Qelbree® for ‘Ms. Represented’ Campaign
Chloe Kim is partnering with Supernus Pharmaceuticals for the 'Ms. Represented' campaign, focusing on ADHD awareness among women. The campaign highlights that over 60% of women diagnosed with ADHD were diagnosed in adulthood. Qelbree, a non-stimulant ADHD treatment, aims to provide support for women experiencing ADHD symptoms.
Read more →SUPNSupernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)
Supernus, Inc. received FDA orphan-drug exclusivity for ONAPGO, effective February 3, 2025. This exclusivity allows for seven years of market protection for the treatment of motor fluctuations in advanced Parkinson's disease. The company also submitted a supplemental New Drug Application for a second supplier, with potential approval expected by mid-2027.
Read more →SUPN▲ +5.2%on this newsshared move
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026
Supernus Pharmaceuticals will announce its third quarter 2026 financial results on October 29, 2026. A conference call will be hosted by CEO Jack Khattar and CFO Tim Dec to discuss these results. The call will be accessible via a live webcast, and a replay will be available afterward on the company's website.
Read more →SUPNSupernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals announced its participation in several investor conferences in September. The company focuses on developing treatments for central nervous system diseases and offers a range of approved products. Investors can arrange meetings with management and access live webcasts of the conferences on the company's website.
Read more →SUPNChloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Chloe Kim has partnered with Supernus Pharmaceuticals to promote awareness of ADHD in adults and the importance of personalized treatment plans. Qelbree, a non-stimulant medication, has become the leading prescribed treatment since its FDA approval five years ago. Kim aims to share her personal experiences to encourage others to discuss their ADHD symptoms and treatment options with healthcare providers.
Read more →SUPNSupernus Announces Second Quarter 2026 Financial Results
Supernus Pharmaceuticals reported a 32% increase in total revenues for Q2 2026, driven by strong sales of its growth products. The company is on track with its regulatory submission for ONAPGO's second supplier and has raised its full-year financial guidance. Additionally, Supernus announced a merger with Indivior Pharmaceuticals, aiming to create a larger CNS biopharmaceutical entity. Despite these positive developments, the company recorded an operating loss and a significant net loss for the quarter.
Read more →SUPNSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
Supernus Pharmaceuticals and Indivior Pharmaceuticals have announced a merger to create a leading CNS biopharmaceutical company. The combined entity, named Supernus, Inc., is expected to generate significant cost synergies and enhance financial flexibility. Jack Khattar will lead the new company, which will have a diverse portfolio of CNS medicines and a strong financial profile. The merger is anticipated to close in Q4 2026, pending regulatory approvals.
Read more →SUPNSupernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Supernus Pharmaceuticals will announce its second quarter 2026 financial results on August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec. The call will allow for investor questions and will be available for replay on the company's website.
Read more →SUPNSupernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
Supernus Pharmaceuticals celebrates the five-year anniversary of Qelbree's FDA approval for ADHD. Qelbree is notable as the first non-stimulant ADHD medication approved in over a decade, with over 3 million prescriptions filled. The drug has expanded its indications to include adults and has received updates to its labeling, enhancing its pharmacodynamic profile. Supernus emphasizes the importance of flexible treatment options for ADHD management.
Read more →SUPNSupernus Expands Partnership With MERGE as AI-Powered Agency of Record
Supernus Pharmaceuticals has expanded its partnership with MERGE, selecting them as the Agency of Record (AOR). This collaboration aims to enhance digital marketing strategies using AI-driven data and technology solutions, focusing on personalized communication for both existing and new products, including QELBREE for ADHD. The expanded partnership illustrates a strong, trust-based relationship developed over seven years and signifies a commitment to innovative healthcare communication experiences. MERGE will manage Supernus's digital ecosystem, supporting their portfolio in CNS diseases.
Read more →SUPNSupernus Pharmaceuticals to Participate in June Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in several investor conferences in June. Investors can arrange meetings with management during these events. A live audio webcast of the Jefferies Global Healthcare Conference will be available on the company's website, along with archived replays for 60 days post-conference. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
Supernus Pharmaceuticals will participate in the Bank of America 2026 Health Care Conference on May 12, 2026. CEO Jack A. Khattar will lead a fireside chat at the event. Investors can arrange meetings with management and access a live audio webcast of the presentation. The company focuses on CNS disease treatments.
Read more →SUPNSupernus Announces First Quarter 2026 Financial Results
Supernus Pharmaceuticals reported strong financial results for Q1 2026, with total revenues of $207.7 million, a 39% increase from the previous year. The company's growth products saw a 56% revenue increase, driven by Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. A regulatory submission for a second supplier of ONAPGO is anticipated in Q3 2026, with potential approval by mid-2027. Despite an operating loss, the company maintains a positive outlook for the year.
Read more →SUPNSupernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
Supernus Pharmaceuticals will report its first quarter 2026 financial results on May 5, 2026, after market close. A conference call will follow at 4:30 p.m. ET, hosted by CEO Jack Khattar and CFO Tim Dec. The call will allow for questions after their prepared remarks. A replay will be available on their Investor Relations website.
Read more →SUPN▲ +5.7%on this news
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Supernus Pharmaceuticals reported record financial results for Q4 and full year 2025, highlighting significant revenue growth and strategic advancements. The company successfully acquired Sage Therapeutics and received FDA approval for ONAPGO, a treatment for Parkinson's disease. Looking ahead, Supernus aims to continue progress on its growth products and pipeline candidates in 2026.
Read more →SUPN▲ +5.1%on this newsshared move
Supernus Pharmaceuticals to Participate in March 2026Investor Conferences
Supernus Pharmaceuticals, Inc. announced its participation in March investor conferences, providing opportunities for investors to meet with management. The company focuses on developing treatments for central nervous system diseases and has a diverse portfolio that includes several approved therapies. Live webcasts of the presentations will be available on their website.
Read more →SUPNSupernus Pharmaceuticals to Participate in March Investor Conferences
Supernus Pharmaceuticals, Inc. has announced its participation in several March investor conferences, including the TD Cowen 46th Annual Health Care Conference and the Barclays 28th Annual Global Healthcare Conference. The management will engage with investors and provide updates on the company’s developments in central nervous system (CNS) therapies. Additionally, the company emphasizes its commitment to a diverse portfolio for treating various CNS diseases, while also acknowledging potential risks associated with future business performance and regulatory approvals.
Read more →SUPNSupernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
Supernus Pharmaceuticals, Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 24, 2026. The announcement will be followed by a conference call hosted by key executives, providing an opportunity for investors to gain insights into the company's performance and future prospects. The company's focus remains on CNS diseases, and despite its diverse portfolio, it faces various risks concerning profitability and regulatory approvals that could impact its financial outlook.
Read more →SUPNSupernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
Supernus Pharmaceuticals will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on December 8, 2025. CEO Jack A. Khattar will lead the presentation, highlighting the company's focus on CNS disease treatments. Investors can access a live audio webcast and arrange meetings with management during the conference.
Read more →About Supernus Pharmaceuticals, Inc.
Headquarters9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850
BIOPHARMAWATCH ELITE PLUS
Trade the next SUPN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime